Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of durvalumab when given together with
chemotherapy in treating patients with solid tumors that have spread to others places in the
body (advanced). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Chemotherapy drugs, such as gemcitabine hydrochloride, pegylated liposomal
doxorubicin hydrochloride, capecitabine, carboplatin, paclitaxel, and nab-paclitaxel work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving chemotherapy with durvalumab
may improve how immune cells respond and attack tumor cells.